Catheter ablation for atrial fibrillation in patients with tricuspid regurgitation
Contemporary guidelines recommend early rhythm control strategies, including catheter ablation (CA) for patients with symptomatic atrial fibrillation (AF). However, the impact of coexisting tricuspid regurgitation (TR) on procedural characteristics and the efficacy of CA for AF remains unclear.
Authors
- Philipp Krisai (ORCID: https://orcid.org/0000-0002-4367-2363)
- Beat A. Kaufmann (ORCID: https://orcid.org/0000-0001-6295-3630)
- Jonas Brügger
- Felix Mahfoud (ORCID: https://orcid.org/0000-0002-4425-549X)
- G Balestra (ORCID: https://orcid.org/0000-0002-5862-0435)
- Michael Kühne (ORCID: https://orcid.org/0000-0002-2937-3711)
- Patrick Badertscher (ORCID: https://orcid.org/0000-0001-9751-0557)
- Fabian Jordan (ORCID: https://orcid.org/0009-0004-4831-7274)
- Sven Knecht (ORCID: https://orcid.org/0000-0001-7122-021X)
- Christian Sticherling (ORCID: https://orcid.org/0000-0001-8428-7050)
- Corinne Isenegger
- David Spreen
- Nicolas Schaerli (ORCID: https://orcid.org/0000-0002-6499-5866)
Institutions
- University of Basel (CH)
- University Hospital of Basel (CH)
Publication Details
- Journal
- Heart Rhythm O2
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1016/j.hroo.2025.05.015
- Citations
- 1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Pfizer
- Foundation for Cardiovascular Research
- Universität Basel
- Boston Scientific Corporation
- Daiichi Sankyo Europe